NPM1 and acute myeloid leukemia: NPM1-mutated CAR-T cells were thus capable of killing in vivo AML cells harboring HLA-A2-positivity and NPM1 mutations, but not HLA-A2-positive lymphoma cells without NPM1-mutated protein, demonstrating killing specificity.